ALK is the abbreviated term for anaplastic large-cell lymphoma kinase, which is part of the Insulin receptor superfamily. ALK rearrangements occur in 2-7% of patients and these people respond to treatment with crizotinib, which has been FDA approved. The most common aberrant fusion gene resulting from an ALK rearrangement is the EML4-ALK fusion gene, but the ALK break-apart probe will detect all rearrangements of ALK.
Genetics - Cytogenetics
CTGN
FFPE FISH
5 days
6085